Skip to content

autologous adipose-derived stromal vascular fraction therapy in Infertility caused by Asherman syndrome

autologous adipose-derived stromal vascular fraction therapy in Infertility caused by Asherman syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17010373
Enrollment
Unknown
Registered
2017-01-10
Start date
2017-03-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female infertility

Interventions

nomoal +SVF treatment:self SVF inject into uter

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
22 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1) Women who have fertility requirements and reproductive rights in line with family planning laws; 2) Women who have a history of uterine cavity operation or pelvic inflammatory disease, with hypomenorrhea or amenorrhea; 3) B-ultrasound or hysterosalpingography showed endometrial meatus or intrauterine adhesions. Hysteroscopy confirmed intrauterine adhesions. Intrauterine adhesions grading medium - severe; 4) aged22 to 40 years; 5) BMI between 18 and 28; 6) Normal ovarian function. anti-Mullerian hormone = 0.5. The third day of menstrual blood FSH between 3 and 10IU / L. The third day of menstrual bilateral ovarian antral follicle count AFC = 6; 7) Informed consent of the subjects, and signed the relevant documents. The process of obtaining informed consent is subject to the GCP; 8) Subjects understand and are willing to actively cooperate with postoperative follow-up and related adjuvant therapy.

Exclusion criteria

Exclusion criteria: 1) Violate the fertility policy; 2) Acute genitourinary system inflammation; 3) Women having diseases in cardiovascular system, digestive system, endocrine system and other system, or infectious diseases,is not prepared for pregnancy; 4) Suffering from genital system tumors or a clear family history of reproductive system tumors; 5) Dysfunction in blood routine, coagulation, liver and kidney, such as BUN/Cr more than the upper limit of normal, ALT/AST/TBIL more than double the upper limit of normal; 6) Mental or neurological disease patients; 7) History of drug or alcohol abuse.

Design outcomes

Primary

MeasureTime frame
total volume of mestrual;thickness of endometrium;shape of uterine cavity;pregnant or not;

Countries

China

Contacts

Public ContactCheng Jiajing

Shanghai Tenth People's Hospital

chengjiajing1963@163.com+86 18917688762

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026